Amplifon walked into this earnings day with the stock up over the past month yet slightly weaker over the past week, a classic setup for investors to test whether recent optimism was justified. The headline is clear: profitability, not just sales, stole the show. Q2 revenue landed at €606m while adjusted EBITDA margin reached 25.8%, which was higher than a year ago. The market now has to decide whether a richer P/E and a modest dividend are still a problem when the core hearing care business is generating stronger cash and better margins.
Is Amplifon a genuine mispriced growth story, or just an expensive stock with flattering forecasts and thin margins? Compare its rich P/E against the cash flows behind it on our valuation analysis for AmplifonQ2 2026 Earnings Summary
- Revenue (Q2 2026 vs Q2 2025): €606m vs €592.7m (up about 2.2%)
- Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): €38.6m vs €35.235m (up about 9.6%)
- Basic EPS (Q2 2026 vs Q2 2025): €0.166 vs €0.157156 (up about 5.6%)
- Adjusted EBITDA Margin (Q2 2026 vs Q2 2025): 25.8% vs about 24.9% (improvement of about 0.9 percentage points)
Prefer clear visuals instead of another wall of earnings tables and margin figures? See Amplifon’s full valuation picture laid out in simple charts and key metrics through the company report for Amplifon..
Evaluating Amplifon’s Growth‑Plus‑Margin Ambition
Bulls argue Amplifon can turn long term hearing demand and Fit4Growth into faster organic growth and higher margins. Q2 goes some way to backing that up. Organic revenue grew 4.7% against an estimated 2.5% market growth, with all three regions contributing and EMEA at 4.5% organic growth. That supports the idea of share gains rather than just riding demographics.
The margin side of the story also moves in the right direction. Adjusted EBITDA margin reached 25.8%, about 90 bps higher year on year, even though Fit4Growth trimmed revenues by roughly 3% to 3.5% and around 200 clinics closed. That is exactly the kind of short term sacrifice for higher structural profitability that the bullish thesis had sketched out. Stronger free cash flow, with H1 rising to €68m and leverage easing toward 1x including equity proceeds, gives more room to fund the GN Hearing acquisition and future M&A.
Compare that improving cash generation, firmer EBITDA margin and deleveraging story with what institutional analysts are baking into their forecasts. See the consensus price target analysis for Amplifon to check how current price targets stack up against Amplifon’s latest earnings progress.Amplifon Bears Still Waiting For a Clear Miss
The core worry around Amplifon is that a bricks and mortar clinic model will lose relevance while heavy investment and Fit4Growth costs quietly erode margins. This quarter does not fully support that. Organic growth of 4.7% with all regions contributing suggests the feared rapid channel shift to online and over the counter is not yet visibly denting volumes. Closing about 200 clinics under Fit4Growth cut revenue by roughly 3% to 3.5%, yet adjusted EBITDA margin reached 25.8%.
Where bears still find ammunition is in execution and mix. The U.S. insurance channel remains soft and France has moved from a reform driven boom to a more ordinary profile. Both highlight that growth still leans on a mature European base and on private pay customers. With a €1.35b loan agreed for GN Hearing, integration and leverage discipline now become the next real test of the bear thesis.
After recent dilution, high debt and softer profit margins, are these just early warning signs or part of a deeper pattern? Review the risk analysis for Amplifon which shows 5 important warning signsTake Charge Of Your Next Move
If Amplifon’s mix of higher adjusted EBITDA margin and stronger cash generation has your attention, register for free with Simply Wall St and add it to a Watchlist to track its share price against fair value and watch for an entry that suits your approach. After you build a position, use the Portfolio Command Center to cut through noise and keep on top of the earnings, valuation and risk updates that matter. For a longer term view, plug into the Community to see how other investors are thinking about Amplifon and similar stocks. This can help you identify potential catalysts and risks early and stay a step ahead of the wider market.
Seeking Alternatives Beyond Amplifon Now
Fresh ideas move first and the strongest stories often break out quietly. Scan focused stock lists while they are still under the radar for now. Act now.
- Spot resilient potential leaders before momentum really starts flying by checking curated 298 resilient stocks with low risk scores that balance measured volatility with underlying business strength.
- Ride the ongoing build out of critical infrastructure by scanning 36 power grid technology and infrastructure stocks that could benefit as grids modernize and capital spending shifts toward new technology.
- Get ahead of the next wave in automation by reviewing focused 36 robotics and automation stocks where machines, software and sensors are already reshaping how industries operate worldwide.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com